[Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].
Tahara
Hideki
H
Tsujimoto
Yoshihiro
Y
Shouji
Tetsuo
T
Inaba
Masaaki
M
Tabata
Tsutomu
T
Nishizawa
Yoshiki
Y
D015415:Biomarkers / Q000097:blood; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage; D003956:Dialysis / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008055:Lipids / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood*; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011073:Polyamines / Q000008:administration & dosage*; D000069603:Sevelamer
D015415:Biomarkers; D008055:Lipids; D010281:Parathyroid Hormone; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium